Filed On Behalf Of:

Aventis Pharma S.A.

By:

DOCKET

Δ

ARM

Dominick A. Conde dconde@fchs.com (212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN LABORATORIES LIMITED Petitioner, v. AVENTIS PHARMA S.A. Patent Owner.

Case IPR2016-00712 U.S. Patent No. 8,927,592

DECLARATION IN SUPPORT OF PATENT OWNER'S MOTION FOR PRO HAC VICE ADMISSION OF JOSHUA I. ROTHMAN UNDER 37 C.F.R. § 42.10

Aventis Exhibit 2254 Mvlan v. Aventis. IPR 2016-00712

Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

1. I, Joshua I. Rothman, am more than twenty-one years of age, am competent to present this declaration, and have personal knowledge of the facts set forth herein.

2. This declaration is given in support of Patent Owner's Motion for *Pro Hac Vice* Admission.

3. I am a partner at the law firm of Fitzpatrick, Cella, Harper & Scinto in the New York office.

4. I have been a patent litigation attorney for more than 17 years. I have been litigating patent cases for this entire time period and have been involved in numerous cases involving patent validity and infringement in District Courts across the country as well as at the Federal Circuit. I have extensive experience in bench trials. A significant portion of my work has involved biological and chemical arts, with particular emphasis on pharmaceuticals. I am, therefore, an experienced litigating attorney.

5. I am a member in good standing of the bar of the State of New York. I am also admitted to the bars of the United States District Court for the Southern and Eastern Districts of New York, the United States Court of Appeals for the Federal Circuit, and the Supreme Court of the United States. I have

1

never been suspended or disbarred from practice before any court or administrative body.

6. No court or administrative body has ever denied my application for admission to practice before it.

7. No court or administrative body has ever imposed sanctions or contempt citations on me.

8. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of 37 C.F.R.

9. I understand that I will be subject to the Office's Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

10. This is my first application to appear *pro hac vice* in a proceeding before the Office.

11. I have an established familiarity with the subject matter at issue in this proceeding. I am familiar with the patent at issue, U.S. Patent 8,927,592 ("the '592 patent"), and the technology at issue. I am also familiar with Patent Owner's legal strategies regarding the patent. I also have extensive knowledge

2

of the assertions regarding the invalidity of the patent. I have also engaged in extensive substantive discussions with experts concerning issues relevant to this proceeding.

 Additionally, I am actively involved in several co-pending
litigations in which the '592 patent is asserted, including (1) Sanofi-Aventis U.S.
LLC et al. v. Fresenius Kabi USA, LLC, C. A. No. 15-2631 (D.N.J.); (2) Sanofi-Aventis U.S. LLC et al. v. Accord Healthcare, Inc., C. A. No. 15-2520 (D.N.J.); (3)
Sanofi-Aventis U.S. LLC et al. v. BPI Labs, LLC et al., C. A. No. 15-2521 (D.N.J.);
(4) Sanofi-Aventis U.S. LLC et al. v. Apotex Corp. et al., C. A. No. 15-1835
(D.N.J.); (5) Sanofi-Aventis U.S. LLC et al. v. Breckenridge Pharmaceutical, Inc.,
C. A. No. 15-1836 (D.N.J.); (6) Sanofi-Aventis U.S. LLC et al. v. Mylan
Laboratories Ltd., C. A. No. 15-3392 (D.N.J.); (7) Sanofi-Aventis U.S. LLC et al.
v. Actavis LLC et al., C. A. No. 15-3107 (D.N.J.); (8) Sanofi-Aventis U.S. LLC et al.
v. Dr. Reddy's Laboratories, Inc. et al., C. A. No. 15-2522 (D.N.J.); and (9)
Sanofi-Aventis U.S. LLC et al. v. Glenmark Pharmaceuticals, Inc. et al., C. A. No.

13. Therefore, I have an established familiarity with the subject matter at issue in this proceeding.

3

14. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the '592 patent.

February 1, 2017

Respectfully submitted,

Joshua I. Rothman FITZPATRICK, CELLA, HARPER & SCINTO 1290 Avenue of the Americas New York, NY 10104-3800 Tel: (212) 218-2100